Israel Cañadas
YOU?
Author Swipe
View article: Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S5. Analysis of the impact of the ER axis on the response to IFNg stimulation in HR+ breast cancer cells.
View article: Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S6. Effect of hormone deprivation and NFKB pathway activation HR+ breast cancer cells.
View article: Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Tables S2-13
View article: Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer Open
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.
View article: Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer
Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer Open
Spliceosome inhibitors emerged as promising anticancer agents. Recent studies have demonstrated that spliceosome-targeted therapies (STTs) trigger antitumor immune responses by inducing the accumulation of right-handed double-stranded (ds)…
View article: Figure S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Figure S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Figure S2 shows TREX1 loss suppresses SCLC growth and induces immune response
View article: Figure S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Figure S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Figure S1 shows TREX1 expression is induced in drug resistant SCLC cells
View article: Table S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Table S2 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Treatment history of PDX tumors
View article: Figure S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Figure S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Figure S3 shows immunogenicity is induced in TREX1 depleted cells
View article: Table S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Table S1 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
qPCR primer sequences
View article: Figure S5 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Figure S5 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Figure S5 shows TREX1 expression is induced in post-treated SCLC PDX
View article: Table S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Table S3 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Drug transporter expression levels in H69AR vs H69
View article: Figure S4 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Figure S4 from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer Open
Figure S4 shows TREX1 depletion increases sensitivity of resistant SCLC cells to chemotherapy
View article: RNA sensing induced by chromosome missegregation augments anti-tumor immunity
RNA sensing induced by chromosome missegregation augments anti-tumor immunity Open
View article: Supplementary Fig. S7 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S7 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.
View article: Supplementary Fig. S7 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S7 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S7. Impact of treatment with fulvestrant, birinapant, and their combination on a PDX model of HR+ breast cancer.
View article: Supplementary Fig. S2 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S2 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S2. Comprehensive analysis of protein expression changes before and after endocrine treatment
View article: Supplementary Fig. S6 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S6 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S6. Effect of hormone deprivation and NFKB pathway activation HR+ breast cancer cells.
View article: Supplementary Fig. S4 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S4 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S4. Schematic of flow cytometry experiments and differential impact of IFNg stimulation on HR+ breast cancer cells.
View article: Supplementary Tables S2-13 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Tables S2-13 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Tables S2-13
View article: Supplementary Fig. S5 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S5 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S5. Analysis of the impact of the ER axis on the response to IFNg stimulation in HR+ breast cancer cells.
View article: Supplementary Fig. S2 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S2 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S2. Comprehensive analysis of protein expression changes before and after endocrine treatment
View article: Supplementary Fig. S8 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S8 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S8. Comprehensive analysis of fulvestrant and birinapant treatment in HR+ breast cancer cell.
View article: Data from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Data from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor positive (HR+) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HR+ breast cancer, we investigated the e…
View article: Supplementary Table S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Table S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Table S1
View article: Supplementary Fig. S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S1. Comprehensive analysis of protein expression data in immune and invasive cancer epithelial regions from in various patient cohorts.
View article: Supplementary Fig. S6 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S6 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S6. Effect of hormone deprivation and NFKB pathway activation HR+ breast cancer cells.
View article: Supplementary Fig. S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S1 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S1. Comprehensive analysis of protein expression data in immune and invasive cancer epithelial regions from in various patient cohorts.
View article: Supplementary Fig. S8 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S8 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S8. Comprehensive analysis of fulvestrant and birinapant treatment in HR+ breast cancer cell.
View article: Supplementary Fig. S3 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer
Supplementary Fig. S3 from Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer Open
Supplementary Fig. S3. Summary of protein expression changes after 24 weeks of endocrine treatment (ET) and/or Palbociclib (palbo) treatment.